๐Ÿ“ฐ NewsThe Drinks Business

Semaglutide cuts heavy drinking days in small alcohol trial

The Drinks Business
Actions
View mode
Semaglutide, the active ingredient in the in-demand diabetes drug Ozempic, reduced heavy drinking days and alcohol-related harm in a phase 2 clinical trial of people with alcohol use disorder. The post Semaglutide cuts heavy drinking days in small alcohol trial appeared first on The Drinks Business .

See an issue with this article, translation, source, or data?

Submit a correction
Related news
Market & crop signal
Coming soon

Crop, import, and price context tied to this article's topic is planned for a future release.